- Home
- DNTH vs VSEC Comparison
DNTH vs VSEC Comparison
Compare DNTH & VSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | VSEC |
|---|---|---|
| Founded | 2015 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.8B |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | DNTH | VSEC |
|---|---|---|
| Price | $111.10 | $217.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $121.00 | ★ $226.29 |
| AVG Volume (30 Days) | ★ 718.6K | 368.3K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.94 |
| Revenue | $2,036,000.00 | ★ $760,113,000.00 |
| Revenue This Year | N/A | $32.16 |
| Revenue Next Year | $29.48 | $21.36 |
| P/E Ratio | ★ N/A | $110.57 |
| Revenue Growth | N/A | ★ 9.88 |
| 52 Week Low | $22.81 | $154.74 |
| 52 Week High | $117.88 | $247.85 |
Technical Indicators
Market Signals| Indicator | DNTH | VSEC |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 50.25 |
| Support Level | $79.27 | $163.12 |
| Resistance Level | $114.55 | $234.92 |
| Average True Range (ATR) | 5.11 | 11.29 |
| MACD | -0.55 | -0.77 |
| Stochastic Oscillator | 42.67 | 27.19 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About VSEC VSE Corporation
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.